Tourmaline Bio to Present at Upcoming Investor Conferences
Tourmaline Bio, Inc. (TRML)
Company Research
Source: GlobeNewswire
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will participate in the following investor conferences in March. Jefferies Biotech on the Bay Summit, MiamiOne-on-one and Small Group Meetings March 12, 2024 Leerink Global Biopharma Conference, MiamiCorporate PresentationMarch 13, 2024 at 10:00am ET Live webcasts and replays, if available, will be posted under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com. About Tourmaline Bio, Inc. Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory disease
Show less
Read more
Impact Snapshot
Event Time:
TRML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRML alerts
High impacting Tourmaline Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TRML
News
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $74.00 price target on the stock.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at Jefferies Financial Group Inc. from $41.00 to $72.00. They now have a "buy" rating on the stock.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.MarketBeat
- Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewswire
TRML
Earnings
- 11/14/23 - Miss
TRML
Analyst Actions
- 3/20/24 - HC Wainwright